ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research note released on Monday, Benzinga reports. Cantor Fitzgerald also issued estimates for ORIC Pharmaceuticals’ FY2024 earnings at ($1.82) EPS. Several other research analysts have also commented on the company. Wedbush reaffirmed an outperform rating and set a […]
More Stories
Why Did Emily Osment Request an Intimate Coordinator for Young Sheldon?
Emily Osment’s recently commented on her behind-the-scenes experience with co-star Montana Jordan during Young Sheldon’s shooting. It is making headlines...
GM Agrees to $220 Million Settlement Over Selling Driver Data
By Naveen Athrappully General Motors (GM) has agreed to a $220 million settlement with a coalition of 36 attorneys general...
Nearly 3 in 10 New-Car Trade-Ins Are Underwater, Edmunds Finds
By Bill Pan Almost three in 10 vehicles traded toward a new car are worth less than the amount still...
Is Fisk Season 4 Releasing? Know About the Release Date, Production Details, and More
Helen Tudor-Fisk is returning for the new season along with the entire cast. ABC has officially announced the renewal of...
Lindsay Clancy Returns to Court as Defense, Prosecutors Discuss 2nd Trial Date
By Stacy Robinson Lindsay Clancy is scheduled to appear in court again on Nov. 2 as her attorneys and prosecutors...
OPEC+ Holds December Crude Oil Output Targets Steady
By Naveen Athrappully Seven core members of OPEC+ have decided to keep December’s required oil production levels unchanged from November....